Genentech Inc. of South San Francisco, Calif., announced Fridaythat Pulmozyme (dornase alfa) is now available commercially.
The recombinant human DNase recently approved by FDA forthe treatment of cystic fibrosis will be sold for $27 per 2.5 mgampule, the recommended daily dose, making the annual costof Pulmozyme $9,855. The figure comes very close to theprojections of many analysts, who have projected revenuesfrom sales of Pulmozyme at $90 million to $93 million in 1994(see BioWorld, Jan. 3).
Genentech (NYSE: GNE) has established a patient-assistanceprogram to help uninsured and underinsured patients receivethe drug. The company stated that it has ample product supplyto meet expected demand. --Karl Thiel
(c) 1997 American Health Consultants. All rights reserved.